Frequently Asked Questions

Yes. In this post hoc analysis of Study 502, adjunctive lumateperone 42 mg plus antidepressant therapy improved sexual functioning more than placebo plus antidepressant therapy over 6 weeks, with a least squares mean difference of 2.7 points on the CSFQ-14 Total score (effect size 0.38; P<.0001). The article notes that a 2- or 3-point difference on the CSFQ-14 Total score has been suggested to be clinically meaningful, so this result was consistent with a modest clinically meaningful improvement.

Sexual dysfunction was very common at baseline. Overall, 82.5% of patients met CSFQ-14 criteria for sexual dysfunction while receiving antidepressant therapy, including 85.0% of women and 76.7% of men. This indicates that sexual dysfunction was already present in most participants before adjunctive lumateperone or placebo was added.

No evidence of worsening was seen over the 6-week double-blind treatment period. In patients without sexual dysfunction at baseline, CSFQ-14 Total scores remained unchanged at Day 43 versus placebo plus antidepressant therapy (LSMD, -0.4; effect size -0.10; P=.7266), and 74.4% of patients in both groups retained normal sexual functioning at the end of treatment. Among those with normal baseline sexual functioning, 20.9% of the lumateperone group and 25.6% of the placebo group shifted to sexual dysfunction.

Among patients with sexual dysfunction at baseline, adjunctive lumateperone was associated with better sexual-function outcomes than placebo. A greater proportion improved to normal sexual function by the end of treatment with lumateperone plus antidepressant therapy (26.3%) than with placebo plus antidepressant therapy (15.2%). The study also found a significant improvement in CSFQ-14 Total score at Day 43 versus placebo in this baseline sexual dysfunction subgroup.

Yes. Women had statistically significant improvement in sexual function with adjunctive lumateperone, whereas men showed numerical improvement that did not reach statistical significance. In women overall, the CSFQ-14 Total score improved versus placebo with an LSMD of 3.5 (effect size 0.47; P<.0001), and in women with baseline sexual dysfunction the LSMD was 3.8 (effect size 0.50; P<.0001). In men overall, the LSMD was 1.9 (effect size 0.33; P=.0791), and in men with baseline sexual dysfunction it was 2.2 (effect size 0.36; P=.0975); the authors state these findings in men should be interpreted cautiously because the male subgroup was relatively small and the analyses were exploratory.

Yes. Adjunctive lumateperone improved all measured CSFQ-14 domains versus placebo at Day 43: pleasure (LSMD, 0.3; effect size 0.39; P<.0001), desire/frequency (LSMD, 0.3; effect size 0.24; P<.05), desire/interest (LSMD, 0.7; effect size 0.39; P<.0001), arousal/excitement (LSMD, 0.6; effect size 0.28; P<.01), and orgasm/completion (LSMD, 0.7; effect size 0.33; P<.001). Both sexes showed significant changes from baseline in pleasure and arousal/excitement, while statistically significant improvements in desire/frequency, desire/interest, and orgasm/completion were observed in women only, with numerical improvements in men.

The sexual-function benefit appeared to track improvement in depressive symptoms to a substantial extent. Change in CSFQ-14 Total score showed a moderate correlation with change in MADRS Total score at Day 22 (r = -0.262) and Day 43 (r = -0.378), and an exploratory mediation analysis suggested that approximately 66.2% of the treatment effect on sexual function was mediated through changes in depressive symptoms. After adjusting for improvement in MADRS Total score, the treatment effect on CSFQ-14 Total score was no longer statistically significant (P=.09).

The sexual-function results came from a post hoc exploratory analysis of Study 502, a phase 3, randomized, double-blind, placebo-controlled trial in adults aged 18 to 65 years with major depressive disorder and inadequate response to 1 or 2 antidepressant courses in the current episode. The trial included 480 randomized patients in the intent-to-treat population, assigned 1:1 to lumateperone 42 mg plus antidepressant therapy (n=242) or placebo plus antidepressant therapy (n=238), with a 6-week double-blind treatment period. Because the sexual-function analysis was post hoc, exploratory, and had no multiplicity adjustment, the reported P values were nominal and should be interpreted descriptively rather than as confirmatory evidence.

The main limitations are that the sexual-function analyses were post hoc and exploratory, the treatment period was short at 6 weeks, and no multiplicity adjustments were applied. Sexual dysfunction was measured by self-report, which can be affected by reporting bias or reluctance to disclose sensitive symptoms, and the study did not assess sexual activity or partnership status. The sample was predominantly White and included relatively few men, which may have limited power for male subgroup analyses and may reduce generalizability.